Hepatitis B virus (HBV) infection is a global public health problem with 350 million people being chronically infected worldwide. People with hepatitis B are at increased risk of developing hepatic decompensation, cirrhosis, and hepatocellular carcinoma[@b1]. China is an endemic region, with a 7.2% prevalence rate of chronic HBV infection in individuals aged 1--59[@b2]. Mother-to-child transmission (MTCT), including intrauterine, labor, postnatal, is considered as one of the main modes of HBV infection. The rate of intrauterine transmission, which accounts for the majority of mother-to-child transmission, among HBsAg positive pregnant women ranges from 5% to 40% in different areas of China[@b3][@b4]. Infants with intrauterine HBV infection have a considerably high risk of becoming chronic carriers. Currently, combined immunoprophylaxis with the utilization of hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) can block most cases of labor and postnatal transmission of HBV. Whereas, HBV intrauterine infection still occurs at high incidence due to lack of effective preventive measures, and its exact underlying mechanisms have not been completely elucidated. Therefore, exploring the risk factors of susceptibility to intrauterine HBV infection will help effectively control the spread of HBV infection among neonates.

Previous studies regarding the factors associated with HBV intrauterine infection were mostly focused on maternal characteristics (i.e. mode of delivery, maternal HBeAg status and viral load)[@b5][@b6]. In addition to maternal characteristics, genetic background may also play an important role in HBV intrauterine infection. However, few studies[@b7][@b8][@b9] had explored the genetic susceptibility to intrauterine infection of HBV, and still, little is known about the associations between genetic factors and HBV intrauterine infection.

Sodium taurocholate cotransporting polypeptide (NTCP), identified as a functional receptor for human hepatitis B virus[@b10], is encoded by the SLC10A1 gene. Variation of the p.S267F (rs2296651) in SLC10A1 gene results in loss of HBV receptor function *in vitro* and was found to be significantly associated with resistance to chronic hepatitis B[@b11]. Meanwhile, Zhenzhen Su *et al*.[@b12] demonstrated that AA genotype of the other locus (rs7154439) in SLC10A1 gene was also associated with HBV clearance. Recently, genome-wide association studies (GWAS) in Japanese and Korean populations determined that single nucleotide polymorphisms (SNPs) in the HLA-DP gene were associated with persistent HBV infection[@b13]. Subsequently, one locus (rs3128917) in the HLA-DP was observed to be associated with chronic HBV infection in the Chinese population[@b14]. The other GWAS conducted in Han Chinese population had identified rs3130542 in HLA-C and rs4821116 in UBE2L3 to be associated with chronic HBV infection[@b15]. Follicular T helper (TfH) cells are newly recognized lineage of CD4^+^ T cells[@b16], which have been reported to be partially responsible for the dysfunction of immune responses during HBV infection[@b17]. CXCR5 and CXCL13 are two of TfH-associated genes, and genetic variants in the CXCR5 gene (rs3922) and CXCL13 gene (rs355687) were reported to be associated with non-responsiveness to the hepatitis B vaccine[@b18]. Toll-like receptors (TLRs), which act as bridging molecules between innate and adaptive immunity, are able to recognize different viruses and/or bacteria by pathogen-associated molecular patterns (PAMPs) and activate a pathogen specific immune response[@b19][@b20]. TLR3, TLR4 and TLR9 are important members of TLR gene family, with TLR3 recognizing virus-derived dsRNA as well as poly I: C, a synthetic dsRNA analogue, TLR4 recognizing lipopolysaccharide, and TLR9 recognizing unmethylated CpG motifs present in bacteria and viruses. Genetic variants in these three genes may influence its biological functions. Rs3775291 in the TLR3 gene was shown to be associated with dsRNA binding capacity[@b21], rs1927914 in the TLR4 gene was found to influence the binding sites of transcriptional factor, promoter activity and gene expression[@b22], and rs352140 in the TLR9 gene was observed to affect the expression of TLR9 gene[@b23]. Hence, we hypothesized that the above 10 SNPs in the 9 genes may modify the risk of intrauterine HBV infection.

Thus we performed this study which aimed to investigate the associations between the 10 SNPs and risk of HBV intrauterine infection. Furthermore, we evaluated the associations of these loci from both maternal and neonatal aspects with HBV intrauterine infection, respectively.

Results
=======

Characteristics of mothers and neonates
---------------------------------------

706 mother-neonate pairs were included in this study and 44 neonates were tested positive for HBsAg and/or HBV DNA. The HBV intrauterine infection rate was 6.23% (44/706). Characteristics of mothers and neonates of cases and controls are summarized in [Table 1](#t1){ref-type="table"}. Mothers in case group were younger than those in control group (*P* = 0.002). While, no statistically significant difference was observed between mothers of cases and controls in the distribution of profession (*P* = 0.804). Additionally, there were no statistically significant differences in birth weight, birth length, gestational weeks and gender between neonates of cases and controls.

Associations between maternal characteristics and HBV intrauterine transmission
-------------------------------------------------------------------------------

As shown in [Table 2](#t2){ref-type="table"}, maternal HbeAg positivity (*P* \< 0.001), maternal HBV DNA positivity (*P* \< 0.001) and caesarean section (*P* = 0.004) were significantly associated with HBV intrauterine transmission. No statistically significant associations were observed between other maternal characteristics and HBV intrauterine transmission.

Associations between maternal and neonatal SNPs and HBV intrauterine infection
------------------------------------------------------------------------------

10 SNPs were successfully genotyped, and basic information about these SNPs is shown in [Supplementary Table S1](#S1){ref-type="supplementary-material"}. The call rate of all the maternal and neonatal SNPs were \>95%, and the genotypes for all SNPs of mothers and neonates in control group conformed to Hard-Weinberg equilibrium (HWE, FDR-*P* \> 0.05). The maternal and neonatal minor allele frequencies (MAFs) in the control group were similar to those in the HapMap database of Han Chinese in Beijing except for the SNP (rs3128917) in HLA-DP which were similar to those in HapMap database of Southern Han Chinese. Distribution of genotypes of the 10 SNPs of mothers and neonates was presented in [Supplementary Tables S2](#S1){ref-type="supplementary-material"} and [S3](#S1){ref-type="supplementary-material"}. Moreover, rs2296651 and rs7154439 were not in strong LD with each other of mothers (r^2^ = 0.008) or neonates (r^2^ = 0.008) in the control group. As shown in [Table 3](#t3){ref-type="table"}, after adjusting for maternal age, maternal HBeAg, maternal HBV DNA and mode of delivery, mothers who carried the rs355687 CT genotypes in CXCL13 gene had a lower risk of HBV intrauterine transmission compared to those who carried CC genotypes (OR = 0.25, 95% CI, 0.08--0.82, *P* = 0.022). Besides, a marginally significantly decreased risk of HBV intrauterine transmission was also found under the dominant model (OR = 0.34, 95% CI, 0.11--1.01, *P* = 0.052). Then, we performed the association analysis for each neonatal SNP under general genetic model, dominant, recessive and additive models. Unfortunately, none of the *P* value was statistically significant after adjustment for maternal age, maternal HBeAg, maternal HBV DNA and mode of delivery. However, the rs3130542 in HLA-C gene of neonates was found to be marginally significantly associated with decreased risk of susceptibility to intrauterine HBV infection under the additive model (OR = 0.55, 95% CI, 0.29--1.04, *P* = 0.064).

Gene-virus interactions with respect to the risk of HBV intrauterine infection
------------------------------------------------------------------------------

[Table 4](#t4){ref-type="table"} shows the results of multiplicative and additive interaction analyses between maternal rs355687, neonatal 3130542 and maternal HBeAg, maternal HBV DNA. Unfortunately, no significant multiplicative or additive interactions were detected.

Interactions between genes and mode of delivery with respect to the risk of HBV intrauterine infection
------------------------------------------------------------------------------------------------------

The results of multiplicative interaction analyses between maternal rs355687, neonatal 3130542 and mode of delivery are shown in [Table 5](#t5){ref-type="table"}. No significant multiplicative interactions between genes and mode of delivery were detected.

Discussion
==========

In this study, we investigated the associations between the genetic variants in 9 candidate genes and risk of HBV intrauterine infection. Our results showed that maternal rs355687 in CXCL13 gene was significantly associated with decreased risk of susceptibility to intrauterine infection of HBV.

Maternal characteristics play an important role in the intrauterine infection of HBV. In our study, we observed that mothers with younger age had a significantly higher risk of HBV intrauterine transmission, which is similar with the results obtained by Schillie *et al*.[@b24]. The possible explanation is that younger mothers were more often HBeAg positive ([Supplementary Table S4](#S1){ref-type="supplementary-material"}) and had longer labors than older mothers[@b25]. Majority of previous studies investigating the influencing factors of HBV intrauterine infection showed that maternal HBeAg positivity and maternal HBV DNA positivity were two main risk factors[@b5][@b26][@b27], which is consistent with our results. Furthermore, we also found that caesarean delivery was a protective factor of HBV intrauterine transmission, which is in agreement with earlier studies[@b5][@b9], indicating that caesarean delivery might help to reduce HBV infection rate of neonates intrauterinely.

Apart from these above factors associated with HBV intrauterine infection, recent studies have suggested that host genetic factors may also have an influence on the susceptibility to HBV intrauterine infection[@b7][@b9][@b28]. In the current study, maternal rs355687 in CXCL13 gene was found to be associated with decreased risk of HBV intrauterine transmission. CXCL13, a molecule of TfH cells, was found to play an integral role in facilitating an effective immune response against HBV by Publicover *et al*.[@b29]. In addition, their study also showed that CXCL13 expression increases in an age-dependent manner[@b30]. The rs355687 is located in the intron of CXCL13 gene, variation of which may affect the transcription of CXCL13 gene. Zhaojun Duan *et al*. found that the rs355687 in CXCL13 gene was associated with non-responsiveness to the hepatitis B vaccine, and the CT genotype in rs355687 appeared more frequently in the group defined as HBV responders (*P*  =  0.038, OR = 0.30, 95% CI, 0.09--0.97)[@b18]. Based on the above findings, we speculated that CT genotype in maternal rs355687 might up-regulate the expression of CXCL13 gene, increase CXCL13 level and clear HBV in the blood of mothers, and thus interrupt HBV transmission from mothers to newborns. Furthermore, no significant association between neonatal rs355687 in CXCL13 gene and HBV intrauterine infection was observed in our study, which was possibly due to the age-dependent manner of CXCL13 production. Notably, we found that the rs3130542 in HLA-C gene of neonates was marginally significantly associated with decreased risk of susceptibility to HBV intrauterine infection under the additive model (OR = 0.55, 95% CI, 0.29--1.04, *P* = 0.064). HLA-C encodes a type I HLA molecule. Increased HLA-C expression in hepatocytes stimulates attack by cytotoxic T cells (CTLs), a crucial component of HBV clearance[@b31][@b32]. Zhibin Hu *et al*. conducted a genome-wide association studies (GWAS) in Chinese population and identified the A allele of rs3130542 in HLA-C gene was associated with chronic HBV infection (OR = 1.33, *P* = 9.49 × 10^−14^)[@b15]. And Montgomery SB *et al*. showed that the A allele of rs3130542 was associated with lower expression of HLA-C[@b33]. Hence, we inferred that neonates carrying the G allele of rs3130542 in HLA-C gene might have a higher expression of HLA-C, which resulted in a decreased risk of HBV intrauterine infection. Subsequently, we ran interaction analyses of the relationship between maternal rs355687, neonatal 3130542 and maternal HBeAg, maternal HBV DNA, mode of delivery and found no significant interactions, which indicated that virological markers (HBeAg, HBV DNA), mode of delivery and host genetic factors might confer susceptibility of HBV intrauterine infection individually. Besides, we did not observe statistically significant associations between other 8 maternal and neonatal SNPs (rs2296651, rs7154439, rs3128917, rs3922, rs3775291, rs1927914, rs352140 and rs4821116) and risk of HBV intrauterine infection. One plausible reason was that the sample size of neonates with HBV intrauterine infection was small in the current study, which resulted in failure to detect the statistically significant associations between them. Another possible explanation was that these SNPs had no effect on the susceptibility to intrauterine infection of HBV essentially.

Some potential limitations in this study should be considered. Firstly, the low incidence of HBV intrauterine infection results in the relatively small sample size of neonates with HBV intrauterine infection, and further studies with larger sample size are needed. Secondly, only one or two SNPs in a gene, reported or identified by previous studies, were selected, so we could not reveal the role of a gene in HBV intrauterine infection comprehensively. Further studies covering all probably functional SNPs in candidate genes are needed. Thirdly, the significant associations found were only at the statistical level and their biological functions were not evaluated. Further biological experiments are therefore warranted to clarify its mechanism underlying the etiology of HBV intrauterine infection, and are among the future studies we plan to pursue.

In summary, our study suggested that maternal rs355687 variant in CXCL13 gene was associated with decreased risk of HBV intrauterine infection. To the best of our knowledge, this is the first study on exploring the roles of host genetic variants in HBV intrauterine infection from both maternal and neonatal aspects. The characterization of functional significance of this particular CXCL13 molecule in HBV intrauterine infection may provide insight leading to the development of novel prophylactic and therapeutic approaches.

Materials and Methods
=====================

Study subjects
--------------

719 HBsAg positive pregnant women were consecutively enrolled in this study from May 2012 to October 2014 at Wuhan Women and Children Medical and Healthcare Center, Wuhan, China. In total, these women delivered 731 neonates, including 12 twins. Women who co-infected with HCV and/or HIV or who gave multiple births were excluded, which yielded 706 mother-neonate pairs eventually.

Maternal information (maternal demographics, characteristics before and during pregnancy), maternal complications, mode of delivery and neonatal characteristics (birth weight, birth length and gender *et al*.) were obtained from medical records. 2-mL procoagulant and 2-mL anticoagulant peripheral venous blood samples of the mothers were collected before delivery, while 2-mL procoagulant and 2-mL anticoagulant femoral venous blood samples of their newborns were collected before the administration of passive-active immunoprophylaxis. Procoagulant blood samples were used for the detection of HBV DNA levels, while anticoagulant blood samples were stored at −80 °C for laboratory testing. After blood collection, the newborns received hepatitis B immune globulin (HBIG) intramuscularly immediately and they were also administered with hepatitis B vaccines at month 0, 1 and 6. This study was approved by the ethics committee of Tongji Medical College of Huazhong University of Science and Technology, and the methods were carried out in accordance with the approved guidelines. Written informed consent was obtained from all mothers.

Serological HBV markers and HBV DNA
-----------------------------------

Information about HBV serological markers of mothers which were detected at the prenatal care visit were acquired from their medical records. HBV DNA levels were tested by RT-PCR (Da'an Gene Co. Ltd, Sun Yat-Sen University, Guangdong, China), which was performed by the staffs of clinical laboratory in the hospital. HBsAg of neonates were measured using ELISA (Kehua biotechnology, Shanghai, China). All procedures were performed according to the manufacturers' instructions. HBV DNA loads \>1 × 10^3^ copies/ml were defined as positive. HBV intrauterine infection was defined as HBsAg and/or HBV DNA positive in neonatal peripheral venous blood within 24 hours of birth and before administration of active or passive immune prophylaxis[@b34]. Newborns with intrauterine HBV infection were classified as case group, those without were classified as control group.

DNA extraction and genotyping
-----------------------------

Genomic DNA was extracted from the blood samples using a TIANamp Blood DNA Kit DP318 (TIANGEN BIOTECH (BEIJING) CO., LTD, China) under the instruction of manufacturer. DNA concentration and optical density were determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). SNPs of each sample were genotyped by the TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA) with a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. For quality control, genotyping was performed without knowing case control status. In addition, samples with a call rate \<80% were removed to make sure the call rate of each SNP was over 95%.

Statistical analysis
--------------------

The Hardy-Weinberg equilibrium (HWE) for genotypes was assessed by a goodness-of-fit *χ*^2^ test among controls. The difference in distribution of demographic characteristics, genotype frequencies between cases and controls were examined by Pearson's *χ*^2^ test or t-test, when appropriate. The association between each SNP of mothers and neonates and risk of intrauterine HBV infection was evaluated by the odds ratio (OR) and its 95% confidence interval (CI) using unconditional multivariable logistic regression model with adjustment for maternal age, maternal HBeAg, maternal HBV DNA level and mode of delivery. In order to avoid the assumption of genetic models, general genetic model, dominant, recessive and additive models were all calculated. Multiplicative and additive interactions were tested to evaluate interactions between genes and virological markers (HBeAg and HBV DNA). Multiplicative interaction was tested to evaluate interactions between genes and mode of delivery. Multiplicative interactions were evaluated by a likelihood ratio test in the logistic regression model. Synergy index (SI), attributable proportion due to interaction (AP), and relative excess risk due to interaction (RERI) and its 95% CIs were calculated in additive interaction analyses. Lack of interaction is indicated by 95% CI of SI containing 1 and 95% CIs of AP and RERI containing 0. All statistical analyses were conducted by SPSS v18.0 (SPSS, Chicago, Illinois, USA). Linkage disequilibrium (LD) was performed using the Haploview v4.2 software, by determining D' and γ^2^ values. The additive interaction analysis was performed using the excel sheet made by Andersson *et al*.[@b35]. All *P* values were two-tailed with a statistically significant level set at 0.05. False discovery test was performed to take into account the multiple comparisons.
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###### Characteristics of mothers and neonates enrolled in the study.

                              **Case neonates (n = 44)**   **Control neonates (n = 662)**    ***P***
  -------------------------- ---------------------------- -------------------------------- -----------
  Maternal Characteristics                                                                 
  Age (years)                        26.43 ± 4.00                   28.36 ± 3.99            **0.002**
  Profession                                                                                  0.804
   Employed                          20/42 (47.6)                  299/655 (45.6)                
   Unemployed                        22/42 (52.4)                  356/655 (54.4)                
  Infant characteristics                                                                   
   Birth weight (g)                   3245 ± 434                     3296 ± 401               0.418
   Birth length (cm)                 50.21 ± 1.49                   50.14 ± 1.56              0.771
   Gestational weeks (w)             39.39 ± 1.10                   39.04 ± 1.34              0.101
  Gender                                                                                      0.073
   Male                              18/44 (40.9)                  358/653 (54.8)                
   Female                            26/44 (59.1)                  295/653 (45.2)                

###### Univariate analyses of associations between maternal characteristics and HBV intrauterine transmission.

  **Characteristics**                               **Case neonates (n = 44)**   **Control neonates (n = 662)**     ***P***
  ------------------------------------------------ ---------------------------- -------------------------------- -------------
  Pre-pregnancy                                                                                                  
   Nulliparas                                              39/43 (90.7)                  516/657 (78.5)              0.057
   Menstrual regularity                                   41/41 (100.0)                  591/608 (97.2)              0.562
   History of abortion                                     13/44 (29.5)                  285/662 (43.1)              0.079
   Family history of HBV infection                          2/44 (4.5)                    37/662 (5.6)               1.000
  Pregnancy                                                                                                      
   Maternal HBeAg positive                                 27/44 (61.4)                  129/628 (20.5)           **\<0.001**
   Maternal HBV DNA positive                               23/35 (65.7)                  185/526 (35.2)           **\<0.001**
   Number of prenatal care visits                                                                                    0.429
   \<10                                                    17/37 (45.9)                  232/589 (39.4)                 
   ≥10                                                     20/37 (54.1)                  357/589 (60.6)                 
   Influenza and/or fever in the first trimester           7/44 (15.9)                   111/662 (16.8)              0.883
   Colporrhagia in the first trimester                     6/44 (13.6)                   129/662 (19.5)              0.339
   Pregnancy-induced hypertension                           3/44 (6.8)                    15/662 (2.3)               0.173
  Delivery                                                                                                       
   Cesarean section                                        21/44 (47.7)                  454/660 (68.8)            **0.004**
   Preterm birth (\<37 weeks)                               2/43 (4.7)                    28/657 (4.3)               1.000
   Premature rupture of membranes                           4/44 (9.1)                   111/662 (16.8)              0.182
   Fetal distress                                          5/44 (11.4)                   75/662 (11.3)               1.000
   Abnormality of umbilical cord                           10/44 (22.7)                  172/662 (26.0)              0.633
   Praevia placenta                                          0/44 (0)                     22/662 (3.3)               0.435

###### Association between maternal and neonatal candidate SNPs and HBV intrauterine infection.

  **Genotypes**    **Cases**   **Controls**   **OR (95% CI)**[\*](#t3-fn1){ref-type="fn"}    ***P***
  --------------- ----------- -------------- --------------------------------------------- -----------
  Mothers                                                                                  
  rs355687                                                                                 
   CC              5 (14.3)     59 (11.1)                          1                             
   CT              12 (34.3)    253 (47.7)                 0.25 (0.08--0.82)                **0.022**
   TT              18 (51.4)    218 (41.1)                 0.45 (0.14--1.41)                  0.172
   Dominant                                                0.34 (0.11--1.01)                **0.052**
   Recessive                                               1.39 (0.67--2.90)                  0.376
   Additive                                                0.96 (0.53--1.76)                  0.904
  Neonates                                                                                 
  rs3130542                                                                                
   AA               2 (4.8)      25 (3.8)                          1                             
   AG              16 (38.1)    218 (33.3)                 0.51 (0.10--2.73)                  0.434
   GG              24 (57.1)    412 (62.9)                 0.29 (0.06--1.51)                  0.140
   Dominant                                                0.36 (0.07--1.82)                  0.219
   Recessive                                               0.52 (0.24--1.13)                  0.097
   Additive                                                0.55 (0.29--1.04)                **0.064**

^\*^Adjusted by maternal age, maternal HBeAg, maternal HBV DNA and mode of delivery in the unconditional logistic regression.

###### Analysis of interactions between HBeAg status, HBV DNA status and maternal *rs355687*, neonatal *rs3130542* and risk of HBV intrauterine transmission.

               **Genotype**   **Cases**   **Controls**   **OR (95% CI)**[\*](#t4-fn1){ref-type="fn"}   ***P***~**mul**~    **SI (95% CI)**       **AP (95% CI)**        **RERI (95% CI)**
  ----------- -------------- ----------- -------------- --------------------------------------------- ------------------ -------------------- ---------------------- -----------------------
  Mothers                                                                                                                                                            
  HBeAg                                                                                                                                                              
   Negative       CT+TT       11 (31.4)    358 (70.9)                         1                             0.758         1.63 (0.13--20.81)    0.36 (−1.15--1.86)    4.48 (−24.60--33.55)
   Positive       CT+TT       19 (54.3)    90 (17.8)                 5.86 (2.33--14.75)                                                                              
   Negative         CC        4 (11.4)     52 (10.3)                 3.23 (0.95--10.99)                                                                              
   Positive         CC         1 (2.9)      5 (1.0)                 12.57 (1.15--137.92)                                                                             
  HBV DNA                                                                                                                                                            
   Negative       CT+TT       8 (22.9)     294 (57.0)                         1                             0.206         0.19 (0.01--5.29)    −2.91 (−12.37--6.55)   −8.92 (−28.35--10.50)
   Positive       CT+TT       22 (62.9)    166 (32.2)                 2.47 (0.93--6.60)                                                                              
   Negative         CC        4 (11.4)      41 (7.9)                 5.12 (1.40--18.70)                                                                              
   Positive         CC         1 (2.9)      15 (2.9)                 2.51 (0.27--23.67)                                                                              
  Neonates                                                                                                                                                           
  HBeAg                                                                                                                                                              
   Negative         GG        7 (16.7)     311 (50.1)                         1                             0.425         1.14 (0.35--3.72)     0.11 (−0.82--1.04)     1.03 (−8.34--10.40)
   Positive         GG        17 (40.5)    85 (13.7)                 6.57 (2.09--20.65)                                                                              
   Negative       AA+AG       9 (21.4)     184 (29.6)                 2.62 (0.88--7.80)                                                                              
   Positive       AA+AG       9 (21.4)      41 (6.6)                 9.22 (2.53--33.62)                                                                              
  HBV DNA                                                                                                                                                            
   Negative         GG        7 (16.7)     262 (40.7)                         1                             0.702         2.06 (0.26--16.20)    0.37 (−0.36--1.10)     1.30 (−1.97--4.56)
   Positive         GG        17 (40.5)    143 (22.2)                 1.80 (0.60--5.36)                                                                              
   Negative       AA+AG       6 (14.3)     163 (25.3)                 1.59 (0.51--4.88)                                                                              
   Positive       AA+AG       12 (28.6)    76 (11.8)                  2.98 (0.95--9.41)                                                                              

*P*~mul~ was calculated using the multiplicative interaction term.

^\*^Adjusted by maternal age, mode of delivery and maternal HBV DNA or maternal HBeAg.

###### Analysis of interactions between mode of delivery and maternal *rs355687*, neonatal *rs3130542* and risk of HBV intrauterine transmission.

                       **Genotype**   **Cases**   **Controls**   **OR (95% CI)**[\*](#t5-fn1){ref-type="fn"}   ***P***~**mul**~
  ------------------- -------------- ----------- -------------- --------------------------------------------- ------------------
  Mothers                                                                                                     
   Mode of delivery                                                                                           
   Cesarean section       CT+TT       11 (31.4)    325 (61.4)                         1                             0.278
   Vaginal delivery       CT+TT       19 (54.3)    145 (27.4)                4.82 (2.09--11.12)               
   Cesarean section         CC        4 (11.4)      47 (8.9)                 4.63 (1.28--16.69)               
   Vaginal delivery         CC         1 (2.9)      12 (2.3)                 5.66 (0.60--53.25)               
  Neonates                                                                                                    
   Mode of delivery                                                                                           
   Cesarean section         GG        11 (26.2)    276 (42.3)                         1                             0.972
   Vaginal delivery         GG        13 (31.0)    135 (20.7)                 3.52 (1.26--9.87)               
   Cesarean section       AA+AG       10 (23.8)    176 (27.0)                 1.93 (0.66--5.64)               
   Vaginal delivery       AA+AG       8 (19.0)     66 (10.1)                 6.63 (2.04--21.56)               

*P*~mul~ was calculated using the multiplicative interaction term.

^\*^Adjusted by maternal age, maternal HBeAg and maternal HBV DNA.
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